New HIV vaccine could expose latent virus and kill it

mediknit, healthcare, hiv
Antiretroviral therapy may soon be obsolete, as scientists have successfully used immune cells to kick the dormant form of HIV out of its hiding place and destroy it. The findings may soon lead to an HIV vaccine.

According to recent estimates, around 1.1 million people in the United States have HIV.

With the help of antiretroviral therapy, over half of these people now have a very low level of the virus.

This means that they can no longer trasmit it to other people.

Antiretroviral therapy can keep HIV in check so well that the virus is near-undetectable in the blood.

However, HIV continues to “live” in latent form, so people with it must keep taking the medications to prevent it from flaring up.

Antiretroviral therapy can have a host of side effects. These may include gastrointestinal problems, cardiovascular problems, insulin resistance, and bleeding events, as well as effects on bone density, liver health, and neurological and psychiatric health.

So, the search for an HIV cure is ongoing. Now, new research may have found a way to “drag” the virus out of its hiding place and neutralize it. The findings may lead to a vaccine that would allow people living with HIV to stop taking antiretroviral medication every day.

Senior study author Robbie Mailliard, Ph.D. — an assistant professor of infectious diseases and microbiology at the University of Pittsburgh Graduate School of Public Health in Pennsylvania — and colleagues have published their findings in the journal EBioMedicine.

Using an entirely different virus to target HIV

Mailliard explains the motivation for their study, saying, “A lot of scientists are trying to develop a cure for HIV, and it’s usually built around the ‘kick and kill’ concept — kick the virus out of hiding and then kill it.”

He adds, “There are some promising therapies being developed for the kill, but the holy grail is figuring out which cells are harboring HIV so we know what to kick.”

In the case of HIV, the virus goes latent by hiding itself in the DNA of T helper immune cells.

To find out which cells are harboring HIV, the team decided to look at a different virus with a similar behavior that affects 95 percent of people living with HIV: cytomegalovirus (CMV).

“The immune system spends a lot of time keeping CMV in check,” explains study co-author Charles Rinaldo, Ph.D., chair of the Department of Infectious Diseases and Microbiology at the University of Pittsburgh.

“In some people, 1 one out of every 5 T cells are specific to that one virus,” adds Rinaldo. “That got us thinking — maybe those cells that are specific to fighting CMV also make up a large part of the latent HIV reservoir.”

“So we engineered our immunotherapy to not only target HIV but to also activate CMV-specific T helper cells.”

Dragging HIV out of its hiding place

So, the researchers took blood from almost two dozen participants who had HIV but were keeping it in check with antiretroviral therapy.

“You have to collect a lot of blood to find T cells latently infected with functional HIV in people on [antiretroviral therapy] — it could be as few as 1 out of every 10 million cells,” explains first study author Jan Kristoff.

The researchers also isolated another type of immune cell called dendritic cells. Mailliard describes these cells using a sports analogy; they are the “quarterbacks” of the immune system, he says, as “they hand off the ball and dictate the plays, telling other immune cells where to go and what to fight.”

In previous studies, scientists used dendritic cells to “make” the immune system kill HIV. Before this study, however, nobody had used them to drag the latent HIV out of its hiding place.

In this research, Mailliard and his team designed “antigen-presenting type 1-polarized, monocyte-derived dendritic cells” (MDC1). They engineered these MDC1 cells to look for and activate CMV-specific T helper cells in the hope that these CMV-specific cells would also hide latent HIV.

Then, the team added MDC1 back to the T helper cells containing latent HIV. This successfully reversed the latency. The virus had to leave its hiding place, making it vulnerable and easy to kill.

“Without adding any other drug or therapy,” explains Mailliard, “MDC1 were then able to recruit killer T cells to eliminate the virally infected cells.”

With just MDC1, we achieved both kick and kill — it’s like the Swiss Army knife of immunotherapies. To our knowledge, this is the first study to program dendritic cells to incorporate CMV to get the kick, and also to get the kill.”

Robbie Mailliard, Ph.D.

Mailliard and his colleagues are now trying to test MDC1 in human clinical trials.

Recent Posts

  • More than eight out of 10 teachers say mental health among pupils in England has deteriorated in the past two years – with rising reports of anxiety, self-harm and even cases of suicide – against a backdrop of inadequate support in schools. In a survey of 8,600 school leaders, teachers and support workers, 83% said they had witnessed an increase in the number of children in their care with poor mental health, rising to 90% among students in colleges. Many described a sense of helplessness in the face of the crisis. One said it was “like a slow-motion car crash for our young people that I am powerless to stop and can’t bear to watch or be part of any more” Others complained that real-terms funding cuts in schools were making it harder to support pupils in need, with fewer support staff available. “We are at a crisis point with mental health,” one respondent said. “Much more anxiety, self-harming. Three suicides in three years in my school alone,” said another. The survey of members of the National Education Union before their conference in Liverpool this week also asked about the support available in schools to pupils in distress. Fewer than half said their school had a counsellor, three out of 10 (30%) had been able to access external specialist support such as NHS child and adolescent mental health services (CAMHS), fewer than 30% had a school nurse and only 12% had a “mental health first aider”, as favoured by the government. More than a third of respondents (37%) had training in the past year to help with supporting young people with mental ill health, but there were complaints that it was often inadequate and ineffective. “Mental health first aid is a lip service,” said one. “Seven members of staff trained – nothing...
  • With the rising influence of tech companies such as Amazon and Google in almost every sphere of life, it may be no surprise that these major players are now venturing into the healthcare space. Emerging healthcare technologies 2019 Our world has become increasingly digitised and this has created the opportunity for electronic devices such as smart speakers to streamline patient experiences. Products currently used by tens of millions of US citizens include Amazon’s Alexa and Google Assistant. These devices have the potential to decrease the time spent manually updating patient records, allowing physicians to spend more time with their patients. Such technologies might also reduce the financial burden on healthcare systems by allowing patients to have certain medical questions answered, book appointments and receive reminders. With this market estimated at about $3.5 trillion the financial incentive for tech companies to enter the healthcare industry is significant. US Health Insurance Portability and Accountability Act Recently, Amazon announced it would allow developers to create HIPAA-compliant healthcare abilities for its electronic assistant, Alexa. These developers will have to comply with HIPAA (the US Health Insurance Portability and Accountability Act of 1996), which functions to ensure the protection of patient information. Programmes currently in development for Alexa will allow patients to access their medical records and check the results of certain medical tests. For instance, Livongo has created a programme for patients to access their blood sugar level readings by voice commands. Amazon has also launched its Comprehend Medical, a machine learning tool that gathers information on physician notes and patient health records. Other companies with electronic assistants, such as Google, have the potential to compete with Amazon in the healthcare sector but will need to catch up with Amazon’s HIPAA compliance if they want to stay competitive. According to the HIPAA Journal, Google...
  • WASHINGTON: India has shortage of an estimated 600,000 doctors and 2 million nurses, say scientists who found that lack of staff who are properly trained in administering antibiotics is preventing patients from accessing live-saving drugs. Even when antibiotics are available, patients are often unable to afford them. High out-of-pocket medical costs to the patient are compounded by limited government spending for health services, according to the report by the Center for Disease Dynamics, Economics & Policy (CDDEP) in the US In India, 65 per cent of health expenditure is out-of-pocket, and such expenditures push some 57 million people into poverty each year. The majority of the world’s annual 5.7 million antibiotic-treatable deaths occur in low- and middle-income countries where the mortality burden from treatable bacterial infections far exceeds the estimated annual 700,000 deaths from antibiotic-resistant infections. Researchers at CDDEP in the US conducted stakeholder interviews in Uganda, India, and Germany, and literature reviews to identify key access barriers to antibiotics in low-, middle-, and high-income countries. Health facilities in many low- and middle-income countries are substandard and lack staff who are properly trained in administering antibiotics. n India, there is one government doctor for every 10,189 people (the World Health Organization (WHO) recommends a ratio of 1:1,000), or a deficit of 600,000 doctors, and the nurse:patient ratio is 1:483, implying a shortage of two million nurses. “Lack of access to antibiotics kills more people currently than does antibiotic resistance, but we have not had a good handle on why these barriers are created,” said Ramanan Laxminarayan, director at CDDEP. The findings of the report show that even after the discovery of a new antibiotic, regulatory hurdles and substandard health facilities delay or altogether prevent widespread market entry and drug availability,” Laxminarayan said in a statement. “Our research shows that of...